Cyprotex Announces a Collaborative Research Agreement with Pfizer
News Nov 02, 2012
The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology.
Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the collaboration: “We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients.
Cocktail Tests on Toxic Waste Called ForNews
Urban waterways receive a cocktail of pollutants, sometimes containing high concentrations of medicines like antidepressants. Surprisingly low concentrations of toxic chemicals can change the way some aquatic creatures swim and feed producing some unexpected results.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018